{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:35:36Z","timestamp":1789180536188,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006206","name":"Biological and Environmental Research","doi-asserted-by":"publisher","award":["KP1605010"],"award-info":[{"award-number":["KP1605010"]}],"id":[{"id":"10.13039\/100006206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006231","name":"Brookhaven National Laboratory","doi-asserted-by":"publisher","award":["DE-SC0012704"],"award-info":[{"award-number":["DE-SC0012704"]}],"id":[{"id":"10.13039\/100006231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006224","name":"Argonne National Laboratory","doi-asserted-by":"publisher","award":["DE-AC02-06CH11357"],"award-info":[{"award-number":["DE-AC02-06CH11357"]}],"id":[{"id":"10.13039\/100006224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01 GM135919"],"award-info":[{"award-number":["R01 GM135919"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35 GM151996"],"award-info":[{"award-number":["R35 GM151996"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P30GM133893"],"award-info":[{"award-number":["P30GM133893"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"U.S. Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006132","name":"Office of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118510","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:47:30Z","timestamp":1766130450000},"page":"118510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Fluorinated HIV-1 protease inhibitors containing chiral hydroxyethylbenzene and indanol as P2\u2032 ligands with potent activity against drug-resistant variants"],"prefix":"10.1016","volume":"304","author":[{"given":"Jagroop","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ean","family":"Spielvogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desaboini","family":"Nageswara Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linah N.","family":"Rusere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ala M.","family":"Shaqra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon J.","family":"Lockbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arooma","family":"Maryam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nese Kurt","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Swanstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia A.","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3491-791X","authenticated-orcid":false,"given":"Akbar","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118510_bib1","unstructured":"Joint United Nations Program on HIV\/AIDS (UNAIDS). Global HIV & AIDS statistics \u2013 Fact Sheet (Updated 10 July 2025); https:\/\/www.unaids.org\/en\/resources\/fact-sheet (Accessed October 20, 2025)."},{"key":"10.1016\/j.ejmech.2025.118510_bib2","year":"2025","journal-title":"AIDS, crisis and the power to transform: UNAIDS Global AIDS Update"},{"key":"10.1016\/j.ejmech.2025.118510_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","article-title":"Current status and prospects of HIV treatment","volume":"18","author":"Cihlar","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ejmech.2025.118510_bib4","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. Available at: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv (Accessed October 20, 2025)."},{"key":"10.1016\/j.ejmech.2025.118510_bib5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.2024.24543","article-title":"Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the international Antiviral Society\u2013USA panel","volume":"333","author":"Gandhi","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.118510_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1021\/ar7001232","article-title":"Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance","volume":"41","author":"Ghosh","year":"2008","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2025.118510_bib7","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1021\/jm049560p","article-title":"Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor","volume":"48","author":"Surleraux","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118510_bib8","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1128\/AAC.44.8.2093-2099.2000","article-title":"BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents","volume":"44","author":"Robinson","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118510_bib9","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/cmdc.202000101","article-title":"Pharmacokinetic parameters of HIV-1 protease inhibitors","volume":"15","author":"Nascimento","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118510_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.chom.2019.06.010","article-title":"The impact of HIV-1 drug escape on the global treatment landscape","volume":"26","author":"Collier","year":"2019","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ejmech.2025.118510_bib11","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1212\/WNL.0b013e318200d727","article-title":"HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study","volume":"75","author":"Heaton","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.ejmech.2025.118510_bib12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrneurol.2016.27","article-title":"HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment","volume":"12","author":"Saylor","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2025.118510_bib13","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41582-023-00879-y","article-title":"Mechanisms underlying HIV-associated cognitive impairment and emerging therapies for its management","volume":"19","author":"Ellis","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2025.118510_bib14","doi-asserted-by":"crossref","first-page":"11762","DOI":"10.1039\/D2CC04541A","article-title":"Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance","volume":"58","author":"Ghosh","year":"2022","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118510_bib15","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1021\/acs.chemrev.0c00648","article-title":"Drug design strategies to avoid resistance in direct-acting antivirals and beyond","volume":"121","author":"Matthew","year":"2021","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2025.118510_bib16","first-page":"1333","article-title":"Combating susceptibility to drug resistance: lessons from HIV-1 protease","volume":"11","author":"King","year":"2004","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118510_bib17","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.bmcl.2006.01.035","article-title":"Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: the discovery of GW0385","volume":"16","author":"Miller","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118510_bib18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jmb.2006.07.073","article-title":"Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring","volume":"363","author":"Cihlar","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118510_bib19","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.28020","article-title":"A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency","volume":"6","author":"Aoki","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2025.118510_bib20","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.chembiol.2013.07.014","article-title":"Substrate envelope-designed potent HIV-1 protease inhibitors to avoid drug resistance","volume":"20","author":"Nalam","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118510_bib21","doi-asserted-by":"crossref","first-page":"8062","DOI":"10.1021\/acs.jmedchem.9b00838","article-title":"HIV-1 protease inhibitors incorporating stereochemically defined P2' ligands to optimize hydrogen bonding in the substrate envelope","volume":"62","author":"Rusere","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118510_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115501","article-title":"HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues","volume":"257","author":"Lockbaum","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118510_bib23","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.1021\/acs.jmedchem.8b00298","article-title":"Design and synthesis of highly potent HIV-1 protease inhibitors containing tricyclic fused ring systems as novel P2 ligands: structure-activity studies, biological and X-ray structural analysis","volume":"61","author":"Ghosh","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118510_bib24","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1039\/c1md00147g","article-title":"Discovery of GS-8374, a potent human immunodeficiency virus type 1 protease inhibitor with a superior resistance profile","volume":"2","author":"He","year":"2011","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2025.118510_bib25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cmdc.201700824","article-title":"Design of highly potent, dual-acting and central-nervous-system-penetrating HIV-1 protease inhibitors with excellent potency against multidrug-resistant HIV-1 variants","volume":"13","author":"Ghosh","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118510_bib26","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications of fluorine in medicinal chemistry","volume":"58","author":"Gillis","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118510_bib27","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02635-18","article-title":"Halogen bond interactions of novel HIV-1 protease inhibitors (PI) (GRL-001-15 and GRL-003-15) with the plap of protease are critical for their potent activity against wild-type HIV-1 and multi-PI-resistant variants","volume":"63","author":"Hattori","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118510_bib28","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1021\/ja00252a056","article-title":"Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines. Mechanism and synthetic implications","volume":"109","author":"Corey","year":"1987","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118510_bib29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/1521-3773(20010105)40:1<40::AID-ANIE40>3.0.CO;2-5","article-title":"Asymmetric catalysis by architectural and functional molecular engineering: practical Chemo- and stereoselective hydrogenation of Ketones","volume":"40","author":"Noyori","year":"2001","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2025.118510_bib30","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1021\/ja954126l","article-title":"Ruthenium(II)-catalyzed asymmetric transfer hydrogenation of ketones using a formic acid\u2212triethylamine mixture","volume":"118","author":"Fujii","year":"1996","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118510_bib31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.80328","article-title":"Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance","volume":"12","author":"Spielvogel","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2025.118510_bib32","doi-asserted-by":"crossref","first-page":"15993","DOI":"10.1073\/pnas.1414063111","article-title":"Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease","volume":"111","author":"Ozen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118510_bib33","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1110\/ps.25502","article-title":"Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease","volume":"11","author":"King","year":"2002","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2025.118510_bib34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/BF01028194","article-title":"Large scale purification and refolding of HIV-1 protease from Escherichia coli inclusion bodies","volume":"12","author":"Hui","year":"1993","journal-title":"J. Protein Chem."},{"key":"10.1016\/j.ejmech.2025.118510_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/srep11286","article-title":"Fluorogenic assay for inhibitors of HIV-1 protease with sub-picomolar affinity","volume":"5","author":"Windsor","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118510_bib36","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1021\/acschembio.9b00370","article-title":"Picomolar to micromolar: elucidating the role of distal mutations in HIV-1 protease in conferring drug resistance","volume":"14","author":"Henes","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118510_bib37","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1021\/acsinfecdis.8b00336","article-title":"Structural adaptation of darunavir analogues against primary mutations in HIV-1 protease","volume":"5","author":"Lockbaum","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2025.118510_bib38","doi-asserted-by":"crossref","first-page":"8296","DOI":"10.1021\/acs.jmedchem.0c00529","article-title":"Structural analysis of potent hybrid HIV-1 protease inhibitors containing bis-tetrahydrofuran in a pseudosymmetric dipeptide isostere","volume":"63","author":"Rusere","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118510_bib39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1107\/S0907444909047337","volume":"66","author":"Kabsch","year":"2010","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.ejmech.2025.118510_bib40","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.118510_bib41","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr., Sect. D: Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.118510_bib42","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr., Sect. D: Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.118510_bib43","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1107\/S0907444909029436","article-title":"Electronic ligand builder and optimization workbench (eLBOW): a tool for ligand coordinate and restraint generation","volume":"65","author":"Moriarty","year":"2009","journal-title":"Acta Crystallogr., Sect. D: Biol. Crystallogr."},{"key":"10.1016\/j.ejmech.2025.118510_bib44","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/355472a0","article-title":"Free R value: a novel statistical quantity for assessing the accuracy of crystal structures","volume":"355","author":"Brunger","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118510_bib45","doi-asserted-by":"crossref","first-page":"W375","DOI":"10.1093\/nar\/gkm216","article-title":"MolProbity: all-atom contacts and structure validation for proteins and nucleic acids","volume":"35","author":"Davis","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.118510_bib46","unstructured":"PyMOL, The Pymol Molecular Graphics System, Version 3.1.6."},{"key":"10.1016\/j.ejmech.2025.118510_bib47","unstructured":"Schr\u00f6dinger, Schr\u00f6dinger Release 2024-1."},{"key":"10.1016\/j.ejmech.2025.118510_bib48","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/jcc.20292","article-title":"Integrated modeling program, applied chemical theory (IMPACT)","volume":"26","author":"Banks","year":"2005","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2025.118510_bib49","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/JVI.02531-09","article-title":"Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance","volume":"84","author":"Nalam","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.118510_bib50","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jmb.2011.03.053","article-title":"Dynamics of preferential substrate recognition in HIV-1 protease: redefining the substrate envelope","volume":"410","author":"Ozen","year":"2011","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118510_bib51","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","article-title":"Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy","volume":"46","author":"Wei","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2025.118510_bib52","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.1128\/JVI.00317-09","article-title":"A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an achilles heel in the virus life cycle","volume":"83","author":"Lee","year":"2009","journal-title":"J. Virol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012759?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425012759?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:08:06Z","timestamp":1773925686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425012759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":52,"alternative-id":["S0223523425012759"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118510","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluorinated HIV-1 protease inhibitors containing chiral hydroxyethylbenzene and indanol as P2\u2032 ligands with potent activity against drug-resistant variants","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118510","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118510"}}